Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 5)

Link copied
Case Copied 84 min read

FEDERAL COURT OF AUSTRALIA

Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 5) [2024] FCA 360

File number: NSD 656 of 2017
Judgment of: NICHOLAS J
Date of judgment: 12 April 2024
Catchwords:

PATENTS – claims for methods of treatment and Swiss-style claims – methods of treatment for primary insomnia characterised by non-restorative sleep and for improving restorative quality of sleep – construction of claims – meaning of non-restorative sleep – meaning of characterised by non-restorative sleep – meaning of restorative quality of sleep – where fourth edition of Diagnostic and Statistical Manual of Mental Disorders (“DSM-IV”) incorporated by reference – construction of claims when read with DSM-IV – whether person skilled in the art must be familiar with DSM-IV– whether claims invalid for lack of clarity – whether invention not fully described in complete specification – whether claims invalid for lack of novelty or inventive step or fair basis – whether supply of respondents’ products constitutes an infringement under s 117(1) read with sub-sec (2)(b) or (c) of Patents Act 1990 (Cth) – whether respondents’ product is a staple commercial product – where respondents’ product capable of being used for non-infringing methods of treatment outside patented indication – whether respondents’ product information document and/or approved indication for respondents’ product constitutes a statement or inducement to use the respondents’ product so as to infringe the method of treatment claims by using it for the patented indication – whether Swiss-style claims infringed – whether respondents’ product a medicament manufactured for treating a patient suffering from primary insomnia characterised by non-restorative sleep and improving restorative quality of sleep – whether respondents authorised infringement of method of treatment claims by medical practitioners prescribing respondents’ product for patented indication – where patented indication and approved indication are different

Held: claims of patent valid, method of treatment claims infringed by supply of respondents’ product and by authorisation of medical practitioners’ infringing use of respondents’ product 

Legislation:

Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)

Patents Act1990 (Cth) ss 7, 13(1), 18, 40(2)(a), 40(3), 88(4), 117

Patents Amendment Act 2001 (Cth) Sch 1, Pt 1

Cases cited:

Actavis UK Ltd v Janssen Pharmaceuticals NV [2008] FSR 35

Aktiebolaget Hässle v Alphapharm Pty Ltd (2002) 212 CLR 411

Allsop Inc v Bintang Ltd (1989) 15 IPR 686

Apotex Pty Limited v Sanofi-Aventis Australia Pty Limited (2013) 253 CLR 284

Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (No 2) (2012) 204 FCR 494

Apotex Pty Ltd v Warner-Lambert Company LLC (No 2) (2016) 122 IPR 17

AstraZeneca AB v Apotex Pty Ltd (2014) 226 FCR 324

AstraZeneca AB v ApotexPty Ltd (2015) 257 CLR 356

Atlantis Corporation Pty Ltd v Schindler (1997) 39 IPR 29

Austal Ships Pty Ltd v Stena Rederi Aktiebolag (2005) 66 IPR 420

Bristol-Myers Squibb Co v Baker Norton Pharmaceuticals Inc [1999] RPC 253

Bristol-Myers Squibb Company v Apotex Pty Ltd (No 5) (2013) 104 IPR 23

Bristol-Myers Squibb Company v F H Faulding & Co Limited

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2024] FCA 360
Decision Date

CaseChat Overview and Summary

Neurim Pharmaceuticals (1991) Ltd sued Generic Partners Pty Ltd for alleged patent infringements in relation to a patent concerning a method of treatment for primary insomnia characterized by non-restorative sleep and for improving restorative quality of sleep. The dispute was heard and determined by the Federal Court of Australia.

The primary legal issues in the case were the validity of the patent claims, the interpretation of specific terms within the claims, and whether the respondents' product or actions constituted an infringement of the patent. The court needed to determine the meaning of terms such as "non-restorative sleep" and "restorative quality of sleep" as used in the patent claims, particularly when read in conjunction with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Additionally, the court had to decide whether the respondents' product, which could be used for non-infringing methods of treatment, infringed the patent, and whether the respondents had authorized the infringement through medical practitioners.

The court held that the claims of the patent were valid and sufficiently clear. It found that the respondents' product did infringe the method of treatment claims by being supplied and by the authorization of medical practitioners to use the product for the patented indication. The court rejected the argument that the respondents' product was a staple commercial product, which could have potentially negated the infringement. It also found that the respondents' product information document and approved indication did not constitute a statement or inducement to use the product in a manner that would infringe the patent. The court concluded that the Swiss-style claims were infringed as the respondents' product was a medicament used for treating primary insomnia characterized by non-restorative sleep and improving restorative quality of sleep. The court found that the respondents had authorized the infringement of the method of treatment claims by medical practitioners prescribing their product for the patented indication, even though the patented and approved indications differed.

The court ordered the parties to provide proposed short minutes of order and to notify the court of any disagreements regarding the scope of the orders. The proceeding was stand over for further orders.

Orders

Orders of the court

1. By 4.00pm 26 April 2024 the parties provide proposed short minutes of order to the Associate to Nicholas J in accordance with his Honour’s reasons published today.

2. By 4.00pm 26 April 2024 the parties provide to the Associate to Nicholas J written notice of the scope of any disagreement between them in relation those parts of the short minutes of order referred to in order 1 that are not agreed.

3. The proceeding stand over to 9.30am on 2 May 2024 for the making of further orders.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

“ICD-10” refers to the tenth edition of the International Statistical Classification of Diseases and Related Health Problems which was published in 1992, and which was current at the priority date. It is a diagnostic system published by the World Health Organization (“WHO”). Background to the Invention The background to the invention is set out as follows at page 1, line 15 to page 3, line 24:Sleep disorders, which are complex, are widespread, especially in Western industrial countries, in which it is estimated that about one third of the adult population reports at least occasional difficulties with sleeping, while at least half of the sleep-disordered population have had sleep complaints for years. In US 5,776,969 (James), which discloses a method of treating various sleep disorders, by therapy with a specified combination of chemical compounds, there is discussed and defined inter alia, primary insomnia, which may or may not be characterized by non-restorative sleep. The definition of primary insomnia in the fourth revision of the [DSM-IV] (American Psychiatric Association, 1994) states: “The predominant complaint is difficulty initiating or maintaining sleep, or non-restorative sleep, for at least one month. The sleep disturbance (or associated daytime fatigue) causes clinically significant distress or impairment in social, occupational or other important areas of functioning.” Furthermore, according to the definition, non-restorative sleep alone is sufficient to establish the diagnosis of primary insomnia, providing it results in impaired daytime functioning. The tenth revision of the International Classification of Diseases (ICD-10) (World Health Organisation, 1991) describes nonorganic insomnia as “a condition of unsatisfactory quantity and/or quality of sleep.” It goes on to state that “there are people who suffer immensely from the poor quality of their sleep, while sleep in quantity is judged subjectively and/or objectively as within the normal limits.”The diagnostic guidelines from ICD-10 state that the essential clinical features for a definitive diagnosis of primary insomnia are as follows: a) the complaint is either of difficulty falling asleep or maintaining sleep, or of poor quality sleep; b) the sleep disturbance has occurred at least three times per week for at least one month; c) there is preoccupation with the sleeplessness and excessive concern over its consequences at night and during the day; d) the unsatisfactory quantity and/or quality of sleep either causes marked distress or interferes with social and occupational functioning. Thus, there is repeated emphasis in ICD-10 on the equal importance of quality of sleep and quantity of sleep in the diagnosis of insomnia. The invention thus relates to primary insomnia (DSM-IV) or nonorganic insomnia (ICD-10). Because, in normal humans, the natural hormone melatonin has an increased nocturnal concentration in the blood (according to a particular profile, see e.g. US 5,498,423 (Zisapel)), compared with its daytime concentration, and because also a lack of nocturnal melatonin appears to correlate with the existence of sleep disorders, especially although not exclusively in the elderly, the possibility of administering exogenous melatonin to ameliorate sleep disorders has been investigated and is the subject of many scientific papers. Thus, for example, in James, S.P., et al. (Neuropsychopharmacology 1990, 3:19-23), melatonin (1 and 5 mg) and placebo were given at 10:45 pm for one night each to 10 polysomnographically pre-screened insomniacs with a mean age of 33.4 years. These patients (who may not necessarily have had non-restorative sleep related insomnia) had quantitative sleep deficits that were demonstrable by PSG. Administration of melatonin did not alter sleep latency, sleep efficiency, total sleep time, or wake after sleep onset. The patients reported improved sleep quality, though they were not more rested in the morning and believed that their total sleep time had been shorter when on melatonin. In Ellis, C.M., et al. (J. Sleep Res., 1996, 5: 61-65), where melatonin (5 mg) was given at 8:00 pm for 1 week to patients with psychophysiological insomnia, there was no reported change in sleep quantity or quality; 8 patients out of 15 were unable to distinguish the period of active melatonin treatment. In Hughes, R.J., et al. (Sleep 1998, 21: 52-68), immediate release and controlled release formulations of melatonin (0.5 and 5 mg) were given 30 min before sleep and additionally, an immediate release preparation of 0.5 mg melatonin was given halfway through the night to polysomnographically prescreened elderly patients with sleep maintenance insomnia. They found that both melatonin preparations reduced sleep latency but did not alter wake time after sleep onset (an important variable in sleep maintenance insomnia) or total sleep time. No melatonin-induced changes in reported sleep quality or daytime measure of mood and alertness were found. MacFarlane J.G., et al. (Biol Psychiatry 1991, 30(4): 371-6) have reported that melatonin (75 mg per os), administered at 10 PM daily to 13 insomniac patients for 14 consecutive days gave a significant increase in the subjective assessment of total sleep time and daytime alertness, whereas 7/13 patients reported no significant effect on subjective feelings of well-being. Thus, there appears to be little or no evidence from published articles, that administration of exogenous melatonin (or other melatonergic agents, melatonin agonists or melatonin antagonists), in the dosages contemplated by the present invention, would be likely to improve the restorative quality of sleep in subjects affected by primary insomnia characterized by non-restorative sleep. However, in contrast with the results of the above published papers, the present inventors have surprisingly found that melatonin (and other melatonergic agents, melatonin agonists or melatonin antagonists) in fact improves the restorative quality of sleep in subjects suffering from primary insomnia. Suitable melatonin agonists and antagonists for use in the present invention include (but are not restricted to) such compounds described in US Patents Nos. US 5,151,446; US 5,318,994; US 5,385,944; US 5,403,851; and International Patent Specification No. WO 97/00069. The Summary of the Invention

Evidence

Evidence Before The Court

Mr Manuel’s evidence was principally directed to the decision of the Secretary of the Department of Health to “down schedule” melatonin dosages of 2 mg or less from Schedule 4 to Schedule 3 with effect from 1 June 2021 and his understanding of the therapeutic indication for Circadin. He described the words “characterised by poor quality sleep” as a “blunt instrument” and “broad term” encompassing a wide range of difficulties with sleep. Ultimately, Mr Manuel’s evidence received very little attention in the parties’ submissions. I do not regard his evidence as of any real assistance in resolving the issues to be determined in this proceeding. To be clear, that is not in any sense a reflection on the quality of Mr Manuel’s evidence (none of which was challenged) or his extensive qualifications and experience as a pharmacist.General Comment on Expert Evidence As to the witnesses’ evidence more generally, I have approached the written evidence of the witnesses, but particularly that of Dr Krapivensky, Dr Behi and Professor Roth, with caution. Regrettably, parts of Dr Krapivensky’s, Dr Behi’s and Professor Roth’s written evidence were overstated, needlessly tendentious and argumentative and, in that respect, not what the Court expects to see from witnesses presenting themselves as independent experts. Parts of their written evidence commenting on the evidence of Professor Wheatley were also quite disrespectful and dismissive in tone. That said, all three witnesses were the subject of detailed and probing questioning in the oral evidence which I generally found more helpful than their written evidence even though it was at times (particularly in the case of Dr Behi) verbose and non-responsive. Professor Wheatley and Professor Glozier were both impressive witnesses who, in my opinion, did their best to assist the Court. Joint Expert Reports There were two expert conclaves held prior to the hearing and two concurrent sessions of expert evidence at the hearing. The first expert conclave included Dr Behi, Dr Krapivensky, Professor Roth, Professor Glozier and Professor Wheatley who together prepared a Joint Expert Report dated 12 February 2020 (“JER 1”). The second expert conclave included Professor Roth, Professor Glozier and Professor Wheatley who together prepared a Joint Expert Report dated 13 February 2020 (“JER 2”). Associate Professor Rawlin and Mr Manuel did not participate in the joint expert conclaves or contribute to the Joint Expert Reports.THE NOTIONAL SKILLED ADDRESSEERelevant Principles The notional skilled addressee is a legal construct and a tool of analysis framed by reference to the available evidence. This will include the patent specification and, typically, evidence of persons with knowledge and experience in the field of the invention. The notional skilled addressee is a person who is likely to have a practical interest in the subject matter of the invention: Catnic Components Ltd v Hill & Smith Ltd [1982] RPC 183 at 242 per Lord Diplock. A person may have a practical interest in an invention at a number of levels. He or she may have an interest in using the products or methods of the invention, making the products of the invention, or making products used to carry out the methods of the invention either alone or in collaboration with others having such an interest: Apotex Pty Ltd v Warner-Lambert Company LLC (No 2) (2016) 122 IPR 17 at [27]. Broadly speaking, the skilled addressee will be a person who also has knowledge and experience in the field of the invention and who will bring to the reading of the relevant document the background knowledge and experience available to those working in that field.

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established